Gordon Freeman, PhD • SITC 2020 Richard V. Smalley, MD, Memorial Award and Lectureship Recipient

SITC 2020 Richard V. Smalley, MD, Memorial Lectureship Speaker

Heslop_Photo_KeynoteDana-Farber Cancer Institute

Richard V. Smalley, MD, Memorial Lectureship
Wednesday, Nov. 11 at 9:30 a.m. EST
The PD-L1/PD-1 Pathway: Discovery and New Insights

Gordon J. Freeman, PhD, is in the Department of Medical Oncology at Dana-Farber Cancer Institute and is a Professor of Medicine at Harvard Medical School. Freeman earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University.

Dr. Freeman’s research identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28). In 2000, Dr. Freeman discovered PD-L1 and PD-L2, and showed they were ligands for PD-1, thus defining the PD-1 pathway and the drug target: block the interaction. Dr. Freeman showed the function of PD-1 was to inhibit immune responses and that blockade enhanced immune responses. Dr. Freeman showed that PD-L1 is highly expressed on many solid tumors such as breast and lung, as well as some hematologic malignancies and allows these tumors to inhibit immune attack. Dr. Freeman is a Fellow of the AACR Academy and received the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology, 2017 Warren Alpert Foundation award, and the 2020 Richard Smalley, MD, memorial award for his work that led to development of PD-1/PD-L1 pathway blockade for cancer immunotherapy.

"This success of PD-L1 and PD-1 immunotherapy has given patients new hope and energized scientists and drug developers as never before. We are finding what works, what's safest, how it works, and who it will work for.
Gordon Freeman, PhD – Dana-Farber Cancer Institute